Opthea Limited Board of Directors

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.

Mr. Kevin Bitter

Mr. Kevin Bitter

VP of Strategy & Corporate Development

Mr. Thomas Charles Reilly

Mr. Thomas Charles Reilly

Chief Financial Officer

Dr. Fang Li Ph.D.

Dr. Fang Li Ph.D.

Senior Vice President of Regulatory Affairs

Ms. Jen Watts

Ms. Jen Watts

VP Global Clinical Operations

Dr. Arshad M. Khanani M.A., M.D.

Dr. Arshad M. Khanani M.A., M.D.

Chief Medical Advisor & Chairman of Medical Advisory Board

Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.

Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.

Founder & Chief Innovation Officer

Ms. Karen Adams CPA

Ms. Karen Adams CPA

VP of Finance & Company Secretary

Mr. Anand Sundaram

Mr. Anand Sundaram

Vice President Marketing

Dr. Julie Clark M.D., M.S.

Dr. Julie Clark M.D., M.S.

Senior Vice President of Clinical Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.